Investigational Monoclonal Antibody for Chronic Hepatitis D Treatment Begins Clinical Trial
Redwood City, Calif-based Bluejay Therapeutics, announced yesterday it had dosed the first patient in their clinical trial, which will evaluate their monoclonal antibody, brelovitug (also known as BJT-778), for the treatment of chronic hepatitis D (CHD).1 The study, named AZURE-1, is a global, randomized clinical trial, examining brelovitug as a monotherapy for adults living with CHD […]
Measles Outbreak Expands to 4 States
This photograph depicts a child who was infected with the measles during a US outbreak in 2024. The child’s cheek shows the characteristic rash associated with this viral infection. Image credit: CDC/ Tatiana Lanzieri, MD, MPH As of March 20, the Centers for Disease Control and Prevention (CDC) is reporting that there are now 378 […]
The Importance to Address and Help Visceral Adiposity in HIV Patients
Theratechnologies has received FDA approval for its supplemental Biologics License Application (sBLA) for EGRIFTA WR (Tesamorelin F8), a newly formulated treatment designed to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The new formulation replaces the previously approved EGRIFTA SV, reducing the dosing frequency from daily to weekly reconstitution, which improves patient convenience […]
Clinical Insights on HIV-Associated Visceral Fat Following FDA Approval of Tesamorelin F8
The FDA has approved Theratechnologies’ supplemental Biologics License Application (sBLA) for EGRIFTA WR (Tesamorelin F8), a new formulation designed to treat excess visceral abdominal fat in adults with HIV-associated lipodystrophy. This version replaces EGRIFTA SV, reducing dosing frequency from daily to weekly reconstitution, improving patient convenience. Tesamorelin F8 maintains bioequivalence to its predecessor while requiring […]
FDA Approves F8 Formulation of Theratechnologies’ Tesamorelin for HIV-Associated Lipodystrophy
The FDA has approved Theratechnologies’ supplemental Biologics License Application (sBLA) for EGRIFTA WR (Tesamorelin F8), a treatment for excess visceral abdominal fat in adults with HIV-associated lipodystrophy. This new formulation replaces EGRIFTA SV, offering weekly reconstitution instead of daily, making it more convenient for patients. Clinical and Pharmacological Advancements: Tesamorelin F8 maintains bioequivalence to the […]
FDA Approves Gepotidacin (Blujepa) for Uncomplicated Urinary Tract Infections
GSK announced today that its antibiotic, gepotidacin (Blujepa), was approved by the FDA. It is is indicated for uncomplicated urinary tract infections in female patients aged at least 12 years and weighing at least 40 kg. “I think with this recent approval, it gives another option. I think to infectious disease hospitalists and family medicine […]
Capvaxive’s EU Approval and Impact on Pneumococcal Disease Prevention: A Focus on At-Risk Populations
Heather Platt, MD, discusses Merck’s ongoing research into real-world effectiveness, cost-effectiveness and a preview to data to be presented at ECCMID 2025. Source link
With the Rise of COVID-19 Vaccines, a Greater Public Mistrust of Immunizations Has Taken Hold
One of the biggest lingering effects that has arisen from the pandemic is vaccine hesitancy and antivaccine beliefs. What started out as a major achievement with the development of new vaccines to protect against COVID-19 in record time, morphed into disinformation and misinformation campaigns about the COVID-19 vaccines and expanded the public’s already existing mistrust […]
EU Approval Progress and Global Access
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for adults 18 and older to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae. The European Commission (EC) is expected to review the recommendation, with a final decision anticipated by Q2 […]
Improving TB Detection and Treatment in Uganda Through Household Screening and Sputum Monitoring
Pulmonary Tuberculosis Chest X-ray : interstitial infiltration at left upper lung due to Mycobacterium Tuberculosis infection Image credits: Unsplash A pilot project in Uganda, running from November 2023 to September 2024, sought to address the challenges of suboptimal tuberculosis (TB) case finding and preventive treatment (TPT) coverage among household contacts (HHCs) of individuals with pulmonary […]
